Festa, Andreas

Elevated Levels of Acute-Phase Proteins and Plasminogen Activator Inhibitor-1 Predict the Development of Type 2 Diabetes

Festa, A., D’Agostino, R., Tracy, R. P., & Haffner, S. M. (2002) · Diabetes

Adipokines, Inflammation, and Metabolic DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,057

Impact of Weight Loss on Inflammatory Proteins and Their Association With the Insulin Resistance Syndrome in Morbidly Obese Patients

Kopp, H. P., Kopp, C. W., Festa, A., Krzyzanowska, K., Kriwanek, S., Minar, E., Roka, R., & Schernthaner, G. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology

Adipokines, Inflammation, and Metabolic DiseasesBariatric Surgery and Outcomes

Cited by 427

Factor Analysis of Metabolic Syndrome Using Directly Measured Insulin Sensitivity

Hanley, A. J. G., Karter, A. J., Festa, A., D’Agostino, R., Wagenknecht, L. E., Savage, P., Tracy, R. P., Saad, M. F., & Haffner, S. (2002) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsDiet, Metabolism, and Disease

Cited by 229

Metabolic and Inflammation Variable Clusters and Prediction of Type 2 Diabetes

Hanley, A. J. G., Festa, A., D’Agostino, R. B., Wagenknecht, L. E., Savage, P. J., Tracy, R. P., Saad, M. F., & Haffner, S. M. (2004) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 198

Differences in Insulin Resistance in Nondiabetic Subjects With Isolated Impaired Glucose Tolerance or Isolated Impaired Fasting Glucose

Festa, A., D’Agostino, R., Hanley, A. J. G., Karter, A. J., Saad, M. F., & Haffner, S. M. (2004) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 180

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study

Simó, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzmàn, J., Dotta, F., Festa, A., Zhou, M., & Kiljański, J. (2015) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 47

Glycaemic outcomes of an Individualized treat Ment a Pproach for old ER vulnerable pat Ients: Arandomized, controlled st Udy in type 2 diabetes Mellitus ( IMPERIUM )

Heller, S. R., Pratley, R. E., Sinclair, A., Festa, A., Kiljański, J., Brusko, C. S., Duan, R., & Heine, R. J. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 18

Remnant cholesterol and long-term incidence of death in coronary artery disease patients

Drexel, H., Mader, A., Larcher, B., Festa, A., Vonbank, A., Fraunberger, P., Leiherer, A., & Saely, C. H. (2025) · Atherosclerosis

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 17

Reduced glucose variability with glucose-dependent versus glucose-independent therapies despite similar glucose control and hypoglycemia rates in a randomized, controlled study of older patients with type 2 diabetes mellitus

Pratley, R. E., Rosenstock, J., Heller, S. R., Sinclair, A., Heine, R. J., Kiljański, J., Brusko, C. S., Duan, R., & Festa, A. (2018) · Journal of Diabetes Science and Technology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 13